Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celgene Links With Array BioPharma

October 1, 2007 | A version of this story appeared in Volume 85, Issue 40

Celgene has linked up with Array BioPharma to discover and develop anticancer and anti-inflammation drugs. Array will receive a $40 million upfront payment in exchange for granting Celgene an option to choose drugs that are directed at two of four mutually selected targets. Array could gain up to $500 million in development and commercial milestones for each drug developed, as well as royalties on commercial sales. Celgene recently struck a similar arrangement with PTC Therapeutics, in which it made a $20 million equity investment in exchange for an exclusive option on two oncology targets for small-molecule drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.